Trial Profile
A Phase 1b/2a study of SI 001 for prostate cancer, melanoma and other solid tumors
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 14 Oct 2019
Price :
$35
*
At a glance
- Drugs ACAM 2000 (Primary)
- Indications Malignant melanoma; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 09 Oct 2019 According to a Calidi Biotherapeutics media release, it is not clear from MR whether company is initiating seperate phase 1b/2 trials for melanoma and other solid tumors. Hence added both the indication in the same trial.
- 01 Nov 2018 New trial record